CD20 × CD3 bispecific T-cell engager
Glofitamab (Specialist drug)
Brand names: Columvi
Adult dose
Dose: Specialist initiation only — refer to BNF/SmPC; step-up dosing on cycle 1
Route: IV
Frequency: per protocol
Clinical pearls
- Relapsed/refractory diffuse large B-cell lymphoma; specialist haem-onc with CRS preparedness
- Pre-treatment with obinutuzumab and dexamethasone reduces CRS
Contraindications
- Active severe infection
Side effects
- Cytokine release syndrome (CRS)
- ICANS / neurotoxicity
- Tumour lysis syndrome
- Neutropenia
- Severe infection
Interactions
- Live vaccines
- Other immunosuppressants
Monitoring
- CRS/ICANS scoring
- FBC
- Uric acid
- Infection screen
Reference: BNF; NICE TA927; SmPC; https://bnf.nice.org.uk/drugs/glofitamab-specialist-drug/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- Vancomycin Dosing Calculator · Drug Dosing
- Phenytoin Correction for Albumin / Renal Failure · Drug Dosing
- Local Anaesthetic Maximum Dose Calculator · Drug Dosing
- Tisdale Risk Score for QT Prolongation · Arrhythmia
- Bazett Corrected QT Interval (QTc) Calculator · Arrhythmia
- DAPT Score for Dual Antiplatelet Therapy Duration · Antiplatelet Therapy
Pathways
- Acute Myeloid Leukaemia Presentation · BSH; NICE — NG146
- Tumour Lysis Syndrome · Cairo-Bishop; BSH; NICE — Best Practice
- Major Haemorrhage / Massive Transfusion · BCSH; RCOA; RCEM; RCS — BCSH Guidelines
- Anaemia Investigation · BSH / NICE
- Splenomegaly Workup · BSH; BMJ Best Practice
- Deep Vein Thrombosis Diagnosis and Treatment · NICE CG144 / NICE NG158